The Increasing Prevalence Of Autoimmune Diseases Is Fueling The Growth Of The Market Due To Rising Demand For TNF-Blocking Therapies: Key Factor Driving The Growth In The Humira Biosimilar Market

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics._x000D_
_x000D_
What Is the Expected Humira Biosimilar Market Size During the Forecast Period?_x000D_
The market size for Humira biosimilars has experienced quick expansion in the past few years. It's projected to increase from $3.28 billion in 2024 to $3.70 billion in 2025, reflecting a compound annual growth rate (CAGR) of 13.0%. The historic growth can be credited to factors such as increasing demand for economical substitutes, rising approvals of biosimilars by regulatory authorities, an increased incidence of autoimmune diseases, the growth of healthcare access in developing markets, and the steep pricing of original biologics._x000D_
_x000D_
The market size for Humira biosimilars is projected to experience swift expansion in the upcoming years, reaching $5.96 billion in 2029 with a compound annual growth rate (CAGR) of 12.6%. This projected growth during the forecast period is credited to advancements in biosimilar development technology, heightened efforts in healthcare cost reduction, the expansion of patent expiry for original biological products, improvements in market accessibility and reimbursement policies, and increased usage of biosimilars in oncology and autoimmune diseases. Significant trends during the forecast period comprise an increase in the approval of additional biosimilars, breakthroughs in manufacturing technologies, expansion in research and development activities, the cultivation and approval of biosimilar drugs, and progress in drug formulation._x000D_
_x000D_
Purchase the full report for exclusive industry analysis:_x000D_
https://www.thebusinessresearchcompany.com/customise?id=24244&type=smp_x000D_
_x000D_
What Are the High-Growth Segments in the Humira Biosimilar Market?_x000D_
The humira biosimilar market covered in this report is segmented -_x000D_
_x000D_
1) By Product Type: Adalimumab Biosimilars, Other Types_x000D_
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels_x000D_
3) By Application: Rheumatoid Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis, Ankylosing Spondylitis, Other Applications_x000D_
_x000D_
Subsegments:_x000D_
1) By Adalimumab Biosimilars: Fully Human Monoclonal Antibodies, Fragment Crystallizable (Fc) Region Modified Biosimilars, High-Concentration Formulations, Citrate-Free Formulations_x000D_
2) By Other Types: Biosimilars Of Other Tumor Necrosis Factor (TNF) Inhibitors, Interchangeable Biosimilars, Pegylated Biosimilars, Non-Adalimumab Monoclonal Antibody Biosimilars_x000D_
_x000D_
Get your free sample here:_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=24244&type=smp_x000D_
_x000D_
What Key Drivers Are Expected to Influence Future Humira Biosimilar Market Growth?_x000D_
Escalating incidences of autoimmune diseases are set to fuel the expansion of the humira biosimilar market. When the immune system erroneously assaults the body's healthy cells, tissues, or organs, autoimmune diseases occur. This rise in autoimmune illnesses is linked to environmental pollution, which interferes with the immune system and increases the likelihood of autoimmune responses. Humira biosimilars function by inhibiting tumor necrosis factor (TNF), a protein that prompts inflammation in autoimmune diseases. This decreases the immune response, easing symptoms and averting damage to healthy tissues. For example, data from the Australian Institute of Health and Welfare, a governmental organization based in Australia, in June 2024 revealed that in 2022, around 514,000 people (2.0%) in Australia were diagnosed with and living with rheumatoid arthritis, with 2.5% being females and 1.6% males. Thus, the escalating incidences of autoimmune diseases provide essential impetus for the growth of the humira biosimilar market._x000D_
_x000D_
Which Companies Hold the Largest Share Across Different Humira Biosimilar Market Segments?_x000D_
Major companies operating in the humira biosimilar market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., LG Chem Ltd., Amgen Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Mylan N.V., Sandoz Group AG, Fresenius Kabi AG, Celltrion Inc., Biocon Limited, Torrent Pharmaceuticals, Samsung Bioepis Co. Ltd., Alvotech, Coherus BioSciences Inc., Zydus Cadila, Hetero Drugs Ltd., Fujifilm Kyowa Kirin Biologics, Synermore Biologics, CVS Health._x000D_
_x000D_
What Are the Major Trends Shaping the Humira Biosimilar Market?_x000D_
Main players in the humira biosimilar industry are prioritizing the creation of innovative products, such as tumor necrosis factor (TNF) inhibitors, to provide cost-effective solutions for managing autoimmune conditions. TNF inhibitors are biologic drugs that hinder the functioning of TNF, a crucial protein that instigates inflammation. For example, in July 2023, Organon & Co., an American pharmaceutical firm, collaborated with Samsung Bioepis Co., Ltd., a biotech corporation based in South Korea, to introduce HADLIMA, a biosimilar to Humira. Available in both citrate-free high-concentration (100 mg/mL) and citrate-containing low-concentration (50 mg/mL) versions, HADLIMA corresponds with the choices provided by the original Humira, attempting to enhance patient affordability and accessibility. With an 85% discount from Humira's listing price, the product also comes with support programs for patients. The introduction of this product, following a worldwide agreement, denotes a significant progress in broadening treatment alternatives for chronic autoimmune diseases in the U.S._x000D_
_x000D_
Get the full report for exclusive industry analysis:_x000D_
https://www.thebusinessresearchcompany.com/report/humira-biosimilar-global-market-report_x000D_
_x000D_
What Are the Emerging Geographies for The Humira Biosimilar Market Growth?_x000D_
North America was the largest region in the humira biosimilar market in 2024. The regions covered in the humira biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
Frequently Asked Questions:_x000D_
1. What Is the Market Size and Growth Rate of the Humira Biosimilar Market?_x000D_
2. What is the CAGR expected in the Humira Biosimilar Market?_x000D_
3. What Are the Key Innovations Transforming the Humira Biosimilar Industry?_x000D_
4. Which Region Is Leading the Humira Biosimilar Market?_x000D_
_x000D_
Why This Report Matters:_x000D_
_x000D_
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors._x000D_
_x000D_
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends._x000D_
_x000D_
Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.